drugset / Trial / NCT00930163

A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

NCT00930163

Phase 2 Completed 218 enrolled Genentech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).

Timeline

Start
2009-07
Primary completion
2010-07
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody Subcutaneous

Indications